Avsnitt
-
In this episode, Dr Robert Cotes and Dr David Goldsmith discuss their clinical experience with long-acting injectable antipsychotic treatments in the Grady Health System, with a focus on communication strategies to educate patients on their treatment options and engage them in shared decision-making.
Presenters:
Robert O. Cotes, MD, DFAPA
Associate Professor and Distinguished Physician
Director, Clinical & Research Program for Psychosis at Grady Health System
Director, Project ARROW at Grady Health System
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, GeorgiaDavid R. Goldsmith, MD, MSc
Associate Professor
Director, Inflammation, Motivation, and Negative Symptoms of Schizophrenia (InMotioNSS) Lab
Co-Director, Clinical & Research Program for Psychosis at Grady Health System
Director, PSTAR Clinic at Grady Memorial Hospital
Faculty, Emory Behavioral Immunology Program
Co-Director, Psychiatry Residency Research Track
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, GeorgiaThis content is part of an online CME program supported by educational grants from Indivior Inc.; Otsuka America Pharmaceutical, Inc. and Lundbeck; and Teva Pharmaceuticals.
Link to full program: https://bit.ly/414XkY4
-
In this episode, David N. Lieberman, MD, PhD, and Eric Marsh, MD, PhD, discuss recent updates relevant to the treatment of Rett syndrome, including:
The recently updated Comprehensive Care Guidelines from the International Rett Syndrome Foundation, available at rettsyndrome.orgOngoing collection and analysis of longitudinal data within the Rett Syndrome Natural History StudyEfficacy and safety data from the double-blind, placebo-controlled phase III registrational LAVENDER trial evaluating oral trofinetide, a small molecule analogue of insulin-like growth factor 1Topline results from phase III AVATAR and EXCELLENCE trials of the sigma-1 receptor agonist blarcamesineSeveral early ongoing gene therapy trialsDr Lieberman and Dr Marsh complement this informative update with wisdom from their own clinical experience to provide a full picture of current treatment and management options available to patients with Rett syndrome.
Presenters:
David N. Lieberman, MD, PhD
Director, Comprehensive Rett Syndrome Clinic
Department of Neurology
Boston Children's Hospital
Boston, MassachusettsEric Marsh, MD PhD
Clinical Director, Orphan Disease Center
Director (MPI), CHOP/Penn IDDRC
Professor, Departments of Neurology and Pediatrics
Division of Neurology
Children’s Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PennsylvaniaThis content is part of an online CME program in partnership with the International Rett Syndrome Foundation and supported by an educational grant from Acadia Pharmaceuticals. Link to full program:
https://bit.ly/4fJRRL0 -
Saknas det avsnitt?
-
Link to CME: Claim Credit - https://bit.ly/3OByCaE
In this episode, Drs. Halford and Hahn discuss the current treatment landscape of developmental and epileptic encephalopathies (DEEs), such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency. The full episode covers:
How to diagnose these epilepsies and the FDA-approved treatment options in the first-line and second-line settingsThe role of antiseizure medications in DEE treatment managementThe nonpharmacological treatment options available to patients with DEEsThe emerging role of brain cholesterol in neurologic diseases like DEEs and Alzheimer’s diseaseResults from the ELEKTRA clinical trial, including cholesterol synthase inhibitors’ impact on seizure frequencyThe future of soticlestat as a treatment option for pediatric patients with DEEsPresenters:
Jonathan J. Halford, MD
Professor
Director, Translational Research Unit
Department of Neurology
Medical University of South Carolina
Charleston, SCCecil Hahn, MD, MPH, FRCPC
Professor
Pediatric Epileptologist
University of Toronto
Toronto, Ontario, CanadaContent based on an online CME program supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Link to full program:
https://bit.ly/45UUpQy -
Link to CME: Claim Credit - https://bit.ly/3wbVkA1
In this episode, Drs. Halford and White discuss the emerging role of brain cholesterol in the development and potential treatment of neurological diseases like epilepsy or Alzheimer and Huntington diseases. The full episode covers:
Overview of brain cholesterol and its function in the bodyPathogenesis potential for certain diseases via brain cholesterolEmerging research on a cholesterol synthase inhibitor as a novel therapyThe future of soticlestat as a potential treatment option for pediatric epilepsies—Lennox-Gastaut syndrome and Dravet syndrome—and other neurological diseasesPresenters:
Jonathan J. Halford, MD
Professor
Director, Translational Research Unit
Department of Neurology
Medical University of South Carolina
Charleston, SCH. Steve White, PhD
Professor, Department of Pharmacy
Co-Director, Center for Epilepsy Drug Discovery
School of Pharmacy
University of Washington
Seattle, Washington -
In this episode, Drs. Sabbagh and Isaacson discuss how to best approach Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in clinical practice, including accurately diagnosing patients and optimizing treatment in terms of patient preferences and reimbursement options. The full episode covers:
Defining AD and MCI and their clinical presentationHow to diagnose AD vs MCIReimbursement landscape for current diagnosing and monitoring toolsPrecision medicine’s evolving role in diagnosing and treating patients with AD and/or MCIPresenters:
Marwan Sabbagh, MD
Professor of Neurology
Alzheimer’s and Memory Disorders Division
Department of Neurology
Barrow Neurological Institute
Phoenix, ArizonaRichard Isaacson MD
Director of the Institute for Neurodegenerative Diseases
Florida -
The treatment landscape of major depression is increasingly shifting from monoaminergic agents to agents that modulate glutamate and GABA. Healthcare professionals need to stay up to date and educated on these changes in order to discuss the most current treatment options with their patients. In this podcast episode, we interview Dr Anita Clayton, a clinician researcher who has been involved in some of the clinical trials for these novel glutamatergic and GABAergic medications, and ask her key questions about mechanism of action and clinical application. Listeners will come away from this podcast episode more informed and more excited for the future of major depression care.
Presenters:
Anita Clayton, MD
David C. Wilson Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
Professor of Clinical Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, VirginiaThis podcast episode is supported by an educational grant from Sage Therapeutics, Inc. and Biogen.
Link to full program:
https://bit.ly/3YdPMPa -
Rett syndrome is a rare but severe neurodevelopmental disorder, and current treatment approaches primarily focus on symptom management and supportive care. However, recent clinical developments are providing hope for a changing treatment landscape. In this podcast episode, experts in Rett syndrome David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, discuss trofinetide and blarcamesine, 2 agents in late-stage clinical trials as treatment options for Rett syndrome. Throughout their conversation, Drs Lieberman and Neul review the pivotal LAVENDER, DAFFODIL, AVATAR, and EXCELLENCE trials, including information on the safety and efficacy profiles of trofinetide and blarcamesine. The experts end their discussion with a conversation about the potential roles of ketamine and gene therapy in the management of Rett syndrome.
Presenters:
David N. Lieberman, MD, PhD
Instructor
Department of Neurology
Harvard Medical School
Attending Physician
Child Neurology
Boston Children’s Hospital
Boston, MassachusettsJeffrey Neul, MD, PhD
Director
Pediatrics
Vanderbilt University Medical Center
Nashville, TennesseeThis activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.
To claim CME/CE credit for this podcast, complete the posttest here:
bit.ly/3JR4qq5.For additional activities in this program, visit
bit.ly/3JR4qq5 -
Rett syndrome affects many organ systems, and each patient has individual symptoms and experiences—there is no “one-size-fits-all” treatment approach. In this podcast episode, Rett syndrome experts David N. Lieberman, MD, PhD, and Shannon Standridge, DO, MPH, discuss some of the more common manifestations of Rett syndrome and current management strategies. While covering manifestations such as epilepsy, behavioral issues, and gastrointestinal distress, they highlight the value of a team approach to help the patient thrive. Throughout their conversation, Drs Lieberman and Standridge weave in real-world examples of interactions they have had with families of patients with Rett syndrome and offer insights on communication strategies for different aspects of management.
Presenters:
David N. Lieberman MD, PhD
Instructor
Department of Neurology
Harvard Medical School
Attending Physician
Child Neurology
Boston Children’s Hospital
Boston, MassachusettsShannon Standridge, DO, MPH
Professor
Division of Neurology
Vinaya Rett Syndrome and Related Spectrum Disorders Clinic
Cincinnati Children’s Hospital Medical Center
Cincinnati, OhioThis activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.
To claim CME/CE credit for this podcast, complete the posttest here:
http://bit.ly/41CeaePFor additional activities in this program, visit
http://bit.ly/3lXuzda -
In this podcast episode, Leslie Citrome, MD, MPH, and Adam Lowy, MD, share a wealth of knowledge about long-acting injectable (LAI) antipsychotics. Their conversation begins with an overview of the pharmacokinetic profiles of LAI antipsychotics and how they differ from their oral counterparts, as well as injection intervals available with current formulations. The experts also discuss the clinical utility of LAI antipsychotics in psychiatry practice, highlighting their role in assuring medication adherence and their application in both first- and later-episode psychosis. Finally, Drs Citrome and Lowy hit on practical aspects of incorporating LAI antipsychotics into patient care: communicating with patients to dispel myths and stigma surrounding injectable medications, identifying injection resources in your medical community, and strategies to navigate insurance barriers.
Throughout the podcast, Drs Citrome and Lowy reference several links to outside sources that can provide valuable education on LAI antipsychotics. Those links are listed below for your convenience.
Administering LAI Into Dorsal Gluteal Site:
https://bit.ly/3XjSm5aAdministering LAI Into Deltoid Site:
https://bit.ly/3Xlyq1LAdministering LAI Into Abdominal Site:
https://bit.ly/3wgGJ2ZPresenters:
Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New YorkAdam Lowy, MD
Staff Psychiatrist
Ellenhorn
Los Angeles, California
This activity is supported by educational funding provided byOtsuka America Pharmaceutical, Inc. and Lundbeck.For additional activities in this program, visit:
https://bit.ly/3iM0HiP -
In this podcast episode, experts in Rett syndrome, David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, provide a comprehensive overview of Rett syndrome (RTT), a rare but severe neurodevelopmental disorder. They begin with a discussion on the clinical characteristics and typical disease progression of RTT before diving into the various genetic markers and how they may, or may not, be used in the diagnosis and prognosis. Finally, the experts ponder the future of RTT diagnoses, touching upon how we might identify RTT and intervene earlier, potential utilization of biomarkers, and the role of measurement-based care.
Presenters:
David N. Lieberman MD, PhD
Instructor
Department of Neurology
Harvard Medical School
Attending Physician
Child Neurology
Boston Children's Hospital
Boston, MassachusettsJeffrey Neul MD, PhD
Director
Pediatrics
Vanderbilt University Medical Center
Nashville, TennesseeThis activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.
To claim CME/CE credit for this podcast, complete the posttest here:
https://bit.ly/3WjtMjAFor additional activities in this program, visit:
https://bit.ly/3kfAn0U -
In this podcast episode, epileptologists Aatif Husain, MD, and John Stern, MD, have a conversation about rescue therapies and how they fit into the spectrum of epilepsy management. Their discussion begins with sharing what they consider the utility of rescue therapies to be in the overall spectrum of epilepsy. As the conversation goes on, they address the role of rescue therapies in more specific patient populations, such as the newly diagnosed patient, a patient experiencing seizure clusters, and patients who may be experiencing either very few or relatively many breakthrough seizure events. In all scenarios, the experts relate the use of rescue therapies as “insurance”—hoping that the agents don’t have to be used, but having them available as coverage in the worst-case scenario. The podcast goes on to discuss rescue therapies in terms of available routes and mechanisms of action and practical strategies for talking to patients about these agents. Rounding out the episode, Drs Husain and Stern express their hopes for future developments in epilepsy management.
Presenters:
Aatif Husain, MD
Professor
Division of Epilepsy, Sleep and Clinical Neurophysiology
Department of Neurology
Duke University Medical Center
Durham, North CarolinaJohn Stern, MD
Professor
Neurology
Geffen School of Medicine, UCLA
Director
Epilepsy Clinical Program
UCLA Department of Neurology
Los Angeles, CaliforniaThis content is based on a CE/CME program supported by an independent educational grant from Neurelis, Inc.
For additional activities in this program, visit
https://bit.ly/3GiLlu4. -
In this podcast episode, Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, have a conversation about Parkinson’s disease psychosis (PDP). Their discussion provides information on the disease itself—covering symptoms, risk factors, and mechanism—before moving into clinical strategies for diagnosis and disease and comorbidity management. The experts emphasize the importance of ruling out an underlying cause of psychosis before making a diagnosis of PDP, calling out common culprits such as urinary and respiratory tract infections. Following diagnosis, they comment on the value of implementing nonpharmacologic measures in tandem with pharmacologic interventions for PDP. Within the discussion of pharmacologic interventions, Drs Sabbagh and San Luciano give a well-rounded explanation of patient and medication factors they consider when choosing a treatment for their patients with PDP, including patient outcomes they have experienced in clinical practice. Rounding out the podcast, the experts touch on their approach to managing the very common comorbidity of sleep disturbances in patients with PDP.
Presenters:
Marwan Sabbagh, MD, FAAN
Professor of Neurology
Alzheimer's and Memory Disorders Division
Department of Neurology
Barrow Neurological Institute
Phoenix, ArizonaMarta San Luciano, MD, MS, FAAN
Associate Professor of Neurology
University of California, San Francisco
Attending Neurologist
Neurology/Movement Disorders and Neuromodulation Center
University of California, San Francisco Medical Center
San Francisco, CaliforniaThis content is based on a CE/CME program supported by an independent educational grant from Acadia Pharmaceuticals, Inc.
For additional activities in this program, visit
http://bit.ly/3tPMqnr -
In this episode, Christoph U. Correll, MD, and John M. Kane, MD, discuss the various etiologies of tardive dyskinesia (TD). Although most healthcare professionals are aware of the risk for TD that comes with first- and second-generation antipsychotic use, there is less awareness around other modifiable and unmodifiable factors that increase risk for TD development. Some modifiable risks include metoclopramide use, anticholinergic use, and substance use disorder; unmodifiable risks include older age and female sex. The doctors agree that, regardless of the level of risk, careful documentation and evaluation should be conducted with patients to detect TD early—should it develop. Their conversation rounds out with considerations for treatment approaches and clinical pearls garnered from years in practice.
Presenters:
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor of Child and Adolescent Psychiatry
Charité – Universitätsmedizin Berlin
Berlin, GermanyJohn M. Kane, MD
Vice President for Behavioral Health Services
Northwell Health
Chairman of Psychiatry
Zucker Hillside Hospital
Queens, New York
Chairman of Psychiatry
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New YorkFor more programs in this series, visit:
https://bit.ly/3AhRXau -
In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the ongoing bipolar disorder research and developments expected to have an impact in the coming year. They elaborate on the various neurotransmitters being investigated and how this research might change the future of patient care. From investigating new mechanisms of action to increased uptake of more novel therapeutics such as esketamine and neuromodulation, there is a lot to look forward to. As they note in the podcast: It’s an exciting time to be in the field of brain science!
Presenters:
Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, MissouriVladimir Maletic MD
Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South CarolinaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.
For more programs in this series, visit:
https://bit.ly/3ft1rYI -
Get answers to the questions that you and your colleagues have asked! In this episode, Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Stuart Isaacson, MD, provide answers to audience questions that were submitted at recent CCO Psychiatry meetings. Their thoughtful responses cover your questions on screening, communicating with patients, medication management, and more. Moderators Rajesh Pahwa, MD; Charles DeBattista, DMH, MD; and Greg W. Mattingly, MD, provide complementary commentary throughout the question and answer session, adding interprofessional perspective to the activity.
Presenters:
Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New YorkCharles DeBattista, DMH, MD
Chief
Depression Research Clinic
Director
Medical Student Education in Psychiatry
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, CaliforniaStuart Isaacson, MD
Director
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, FloridaGreg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, MissouriJonathan M. Meyer MD
Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis ProgramRajesh Pahwa, MD
Chief, Parkinson and Movement Disorder Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, KansasFor more programs in this series, visit:
https://bit.ly/3Bg0oTv -
In this episode, Joseph F. Goldberg, MD, and Roger McIntyre, MD, FRCPC, shed light on the symptom improvement timeline in bipolar depression. This is a topic made more complex when factoring in individual patient characteristics and comorbidities, but the 2 experts have astute insights on how to tailor a management plan based on such factors. They cover symptom management and improvement from a variety of angles, including evaluating improvement in functionality and mood, guidance on follow-up and dose adjustment schedules, the utility of measurement-based care, and—of most importance—how to best communicate with and support a patient while they work towards remission and recovery.
Presenters:
Joseph F. Goldberg, MD
Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New YorkRoger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, CanadaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.
For more programs in this series, visit:
https://bit.ly/3ft1rYI -
In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia from identification to follow-up and ongoing management. They provide valuable insights on pharmacologic options to both consider and avoid to optimize outcomes in patients with tardive dyskinesia, including a focus on clinical strategies for use of VMAT2 inhibitors.
Presenters:
Robert O. Cotes, MD
Associate Professor
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, GeorgiaJonathan M. Meyer, MD
Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program -
In this podcast episode, Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, provide a wealth of information on VMAT2 inhibitors and their use for tardive dyskinesia (TD) management. Their discussion includes information on VMAT2 inhibitor emergence in clinical practice, mechanism of action, adverse event profiles, insurance coverage, and strategies for initiation and titration. In addition to VMAT2 inhibitors, the experts touch on off-label options for TD management and their place in the TD management paradigm.
Presenters:
Diana O. Perkins, MD, MPH
Professor, Psychiatry
University of North Carolina at Chapel Hill
Chapel Hill, North CarolinaRajiv Tandon, MD
Emeritus Professor of Psychiatry
Department of Psychiatry
Western Michigan University Homer Stryker MD College of Medicine
Kalamazoo, MichiganThis content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences.
For more programs in this series, visit:
https://bit.ly/3yOL8f7 -
In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, share their thoughts on treatment strategies across the bipolar depression spectrum. They begin by talking about their stance on treating bipolar with comorbidities with a holistic vs stepwise approach and discuss what strategies they would consider for a patient not yet diagnosed with but who is at risk of developing bipolar depression. In addition, they discuss the concept of phase-specific treatment, considerations for medication-related adverse events, and the utility of adjunctive measures for managing bipolar depression.
Presenters:
Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, MissouriVladimir Maletic MD
Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South CarolinaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.
For more programs in this series, visit:
https://bit.ly/3TClDqb -
In this podcast episode on tardive dyskinesia (TD), Joseph P. McEvoy, MD, interviews Leslie, a patient who was diagnosed with TD 10 years ago. She describes her journey to an accurate diagnosis, the impact that TD has on her daily life, and her advice for patients and providers affected by TD.
Presenters:
Joseph P. McEvoy MD
Professor
Psychiatry and Health Behavior
Psychiatrist
Augusta University
Augusta, GeorgiaLeslie
This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.
For more programs in this series, visit:
https://bit.ly/3dUCVi6 - Visa fler
